Little Rock, AR, United States of America

Srinivas Ayyadevara

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Bioventures, LLC, The United States Government as Represented by the Department of Veterans Affairs. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Srinivas Ayyadevara

Introduction

Srinivas Ayyadevara is an accomplished inventor based in Little Rock, AR (US). He has made significant contributions to the field of neurodegeneration through his innovative research and patent.

Latest Patents

Ayyadevara holds a patent for "Methods of protecting against neurodegeneration." This patent provides a method for preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also outlines methods for reducing the risk, delaying the onset, slowing the progression, or reversing the signs or symptoms of neurodegenerative diseases using CA4. The compound may bind to glial fibrillary acidic protein (GFAP) and is described by compounds of Formula (I). He has 1 patent to his name.

Career Highlights

Throughout his career, Ayyadevara has worked with notable organizations, including the United States Government as represented by the Department of Veterans Affairs and Bioventures, LLC. His work has focused on advancing the understanding and treatment of neurodegenerative diseases.

Collaborations

Ayyadevara has collaborated with esteemed colleagues such as Robert Shmookler Reis and Peter Crooks. These partnerships have contributed to the development of innovative solutions in his field.

Conclusion

Srinivas Ayyadevara's work in neurodegeneration showcases his dedication to advancing medical science. His innovative methods and collaborations highlight the importance of research in combating age-progressive diseases.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…